DISCLAIMER

Use of trade names is for identification only and does not imply endorsement by the Agency for Toxic Substances and Disease Registry, the Public Health Service, or the U.S. Department of Health and Human Services.
This toxicological profile is prepared in accordance with guidelines developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the Federal Register on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a relevance to public health discussion which would allow a public health professional to make a real-time determination of whether the presence of a particular substance in the environment poses a potential threat to human health. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to the protection of public health are identified by ATSDR.

Each profile includes the following:

(A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance due to associated acute, intermediate, and chronic exposures;

(B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, intermediate, and chronic health effects; and

(C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR’s assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.

Patrick N. Breysse, Ph.D., CIH
Director, National Center for Environmental Health and
Agency for Toxic Substances and Disease Registry

Christopher M. Reh, Ph.D.
Associate Director
Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention
*Legislative Background*

The toxicological profiles are developed under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 104(i)(1) directs the Administrator of ATSDR to “…effectuate and implement the health related authorities” of the statute. This includes the preparation of toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL) and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the NPL, in an effort to “…establish and maintain inventory of literature, research, and studies on the health effects of toxic substances” under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.
## VERSION HISTORY

<table>
<thead>
<tr>
<th>Date</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>January 2022</td>
<td>Final toxicological profile released</td>
</tr>
<tr>
<td>December 2019</td>
<td>Draft for public comment toxicological profile released</td>
</tr>
<tr>
<td>September 2002</td>
<td>Final toxicological profile released</td>
</tr>
<tr>
<td>April 1993</td>
<td>Final toxicological profile released</td>
</tr>
<tr>
<td>June 1989</td>
<td>Final toxicological profile released</td>
</tr>
</tbody>
</table>
CONTRIBUTORS & REVIEWERS

CHEMICAL MANAGER TEAM

Rae T. Benedict, Ph.D. (Lead)  Kimberly Zaccaria, Ph.D., D.A.B.T.
Sam Keith, M.S., C.H.P.  Heather Carlson-Lynch, M.S., D.A.B.T.
Hana Pohl, M.D., Ph.D.  Julie Melia, Ph.D., D.A.B.T.
Mike Fay, Ph.D.  Deborah Herber, Ph.D.

Parker Honey, M.P.H.  Courtney Hard, B.A.
Mario Citra, Ph.D.  Hana Pohl, M.D., Ph.D.

ATSDR, Office of Innovation and Analytics, Toxicology Section, Atlanta, GA  SRC, Inc., North Syracuse, NY

REVIEWERS

Interagency Minimal Risk Level Workgroup:
Includes ATSDR; National Center for Environmental Health (NCEH); National Institute for Occupational Safety and Health (NIOSH); U.S. Environmental Protection Agency (EPA); National Toxicology Program (NTP).

Additional reviews for science and/or policy:
ATSDR, Office of Community Health and Hazard Assessment; ATSDR, Office of Capacity Development and Applied Prevention Science; ATSDR, Office of Science; NCEH, Division of Laboratory Science; NCEH, Division of Environmental Health Science and Practice; EPA, Center for Public Health and Environmental Assessment.

PEER REVIEWERS

1. Tee L. Guidotti, M.D., MPH; Retired Chair of the Department of Environmental and Occupational Health and Director of the Division of Occupational Medicine and Toxicology at George Washington University; Affiliate with Risk Sciences International Inc., Silver Spring, Maryland
2. J. E. Klaunig, Ph.D., Fellow ATS, Fellow IATP; Professor, Environmental Health; Professor, School of Public and Environmental Affairs; Indiana University Bloomington; Bloomington, Indiana
3. Emily S. Barrett, Ph.D.; Associate Professor, Department of Epidemiology; Environmental and Occupational Health Sciences Institute; Rutgers School of Public Health; Piscataway, New Jersey

These experts collectively have knowledge of toxicology, chemistry, and/or health effects. All reviewers were selected in conformity with Section 104(i)(13) of the Comprehensive Environmental Response, Compensation, and Liability Act, as amended.

ATSDR scientists review peer reviewers’ comments and determine whether changes will be made to the profile based on comments. The peer reviewers’ comments and responses to these comments are part of the administrative record for this compound.

The listing of peer reviewers should not be understood to imply their approval of the profile's final content. The responsibility for the content of this profile lies with ATSDR.
CONTENTS

DISCLAIMER .........................................................................................................................ii
FOREWORD ............................................................................................................................iii
VERSION HISTORY ..............................................................................................................v
CONTRIBUTORS & REVIEWERS ..........................................................................................vi
CONTENTS ..........................................................................................................................vii
LIST OF FIGURES ................................................................................................................ix
LIST OF TABLES ..................................................................................................................x

CHAPTER 1. RELEVANCE TO PUBLIC HEALTH ................................................................. 1
  1.1 OVERVIEW AND U.S. EXPOSURES ........................................................................... 1
  1.2 SUMMARY OF HEALTH EFFECTS ......................................................................... 3
  1.3 MINIMAL RISK LEVELS (MRLs) ............................................................................ 11

CHAPTER 2. HEALTH EFFECTS ......................................................................................... 15
  2.1 INTRODUCTION ......................................................................................................... 15
  2.2 DEATH ...................................................................................................................... 99
  2.3 BODY WEIGHT ........................................................................................................ 100
  2.4 RESPIRATORY .......................................................................................................... 115
  2.5 CARDIOVASCULAR ............................................................................................... 117
  2.6 GASTROINTESTINAL ............................................................................................ 123
  2.7 HEMATOLOGICAL ................................................................................................. 124
  2.8 MUSCULOSKELETAL ............................................................................................ 126
  2.9 HEPATIC ................................................................................................................ 127
  2.10 RENAL .................................................................................................................. 141
  2.11 DERMAL ............................................................................................................... 145
  2.12 OCULAR .............................................................................................................. 146
  2.13 ENDOCRINE ....................................................................................................... 146
  2.14 IMMUNOLOGICAL ............................................................................................... 164
  2.15 NEUROLOGICAL ................................................................................................. 174
  2.16 REPRODUCTIVE ................................................................................................. 176
  2.17 DEVELOPMENTAL .............................................................................................. 216
  2.18 OTHER NONCANCER .......................................................................................... 288
  2.19 CANCER ............................................................................................................... 297
  2.20 GENOTOXICITY .................................................................................................... 301

CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS ................................................................................................................. 312
  3.1 TOXICOKINETICS .................................................................................................... 312
     3.1.1 Absorption ....................................................................................................... 312
     3.1.2 Distribution ..................................................................................................... 316
     3.1.3 Metabolism ...................................................................................................... 320
     3.1.4 Excretion ......................................................................................................... 324
     3.1.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models .......................................................... 330
     3.1.6 Animal-to-Human Extrapolations .................................................................. 337
  3.2 CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE .............................................................. 337
  3.3 BIOMARKERS OF EXPOSURE AND EFFECT ............................................................ 343
     3.3.1 Biomarkers of Exposure ............................................................................... 344
     3.3.2 Biomarkers of Effect ....................................................................................... 346
  3.4 INTERACTIONS WITH OTHER CHEMICALS ............................................................. 346
CHAPTER 4. CHEMICAL AND PHYSICAL INFORMATION .......................................................... 355
4.1 CHEMICAL IDENTITY ........................................................................................................... 355
4.2 PHYSICAL AND CHEMICAL PROPERTIES ........................................................................ 356

CHAPTER 5. POTENTIAL FOR HUMAN EXPOSURE .................................................................. 357
5.1 OVERVIEW .............................................................................................................................. 357
5.2 PRODUCTION, IMPORT/EXPORT, USE, AND DISPOSAL ................................................ 359
  5.2.1 Production ........................................................................................................................ 359
  5.2.2 Import/Export ................................................................................................................... 361
  5.2.3 Use .................................................................................................................................... 361
  5.2.4 Disposal ............................................................................................................................ 362
5.3 RELEASES TO THE ENVIRONMENT.................................................................................... 363
  5.3.1 Air ..................................................................................................................................... 365
  5.3.2 Water ................................................................................................................................ 367
  5.3.3 Soil .................................................................................................................................... 368
5.4 ENVIRONMENTAL FATE ...................................................................................................... 370
  5.4.1 Transport and Partitioning ............................................................................................... 370
  5.4.2 Transformation and Degradation ..................................................................................... 372
5.5 LEVELS IN THE ENVIRONMENT .......................................................................................... 373
  5.5.1 Air ..................................................................................................................................... 376
  5.5.2 Water ................................................................................................................................ 378
  5.5.3 Sediment and Soil ............................................................................................................ 379
  5.5.4 Other Media ....................................................................................................................... 380
5.6 GENERAL POPULATION EXPOSURE.................................................................................. 384
5.7 POPULATIONS WITH POTENTIALLY HIGH EXPOSURES .............................................. 416

CHAPTER 6. ADEQUACY OF THE DATABASE .......................................................................... 420
6.1 Information on Health Effects ............................................................................................... 420
6.2 Identification of Data Needs ................................................................................................ 422
6.3 Ongoing Studies ..................................................................................................................... 426

CHAPTER 7. REGULATIONS AND GUIDELINES ........................................................................ 429

CHAPTER 8. REFERENCES .......................................................................................................... 431

APPENDICES
APPENDIX A. ATSDR MINIMAL RISK LEVEL WORKSHEETS ................................................. A-1
APPENDIX B. LITERATURE SEARCH FRAMEWORK FOR DEHP ........................................... B-1
APPENDIX C. USER’S GUIDE ....................................................................................................... C-1
APPENDIX D. QUICK REFERENCE FOR HEALTH CARE PROVIDERS .................................... D-1
APPENDIX E. GLOSSARY ............................................................................................................ E-1
APPENDIX F. ACRONYMS, ABBREVIATIONS, AND SYMBOLS ................................................. F-1
LIST OF FIGURES

1-1. Health Effects Found in Animals Following Inhalation Exposure to DEHP ........................................ 4
1-2. Health Effects Found in Animals Following Oral Exposure to DEHP ................................................ 5
1-3. Summary of Sensitive Targets of DEHP – Inhalation ........................................................................ 12
1-4. Summary of Sensitive Targets of DEHP – Oral ................................................................................. 13
2-1. Overview of the Number of Studies Examining DEHP Health Effects .............................................. 19
2-2. Levels of Significant Exposure to DEHP – Inhalation ....................................................................... 23
2-3. Levels of Significant Exposure to DEHP – Oral ................................................................................ 86
3-1. Metabolic Pathway of DEHP ............................................................................................................. 321
5-1. Number of NPL Sites with DEHP Contamination ........................................................................... 357
6-1. Summary of Existing Health Effects Studies on DEHP By Route and Endpoint ............................... 421
LIST OF TABLES

1-1. Minimal Risk Levels (MRLs) for DEHP ................................................................. 14

2-1. Levels of Significant Exposure to DEHP – Inhalation ........................................ 20

2-2. Levels of Significant Exposure to DEHP – Oral ............................................... 25

2-3. Selected Epidemiological Studies of DEHP Exposure and Body Weight Metrics ... 101

2-4. Selected Epidemiological Studies of DEHP Exposure and Blood Pressure .......... 119

2-5. Selected Epidemiological Studies of DEHP Exposure and Serum Lipid/Cholesterol Alterations .............................................................. 128

2-6. Summary of Epidemiological Studies of DEHP Exposure and Thyroid Hormone Levels .... 147

2-7. Selected Epidemiological Studies of DEHP Exposure and Allergy, Asthma, and Atopy 165

2-8. Summary of Epidemiological Studies of DEHP Exposure and Serum Reproductive Hormones or Leydig Cell Functionality in Adult Men ............................ 178

2-9. Summary of Epidemiological Studies of DEHP Exposure and Sperm Parameters .... 187

2-10. Summary of Epidemiological Studies of DEHP Exposure and Female Reproductive Effects .... 198

2-11. Summary of Epidemiological Studies of Prenatal DEHP Exposure and Pregnancy Outcomes .... 203

2-12. Summary of Epidemiological Studies of Prenatal DEHP Exposure and Birth Size ... 217


2-14. Summary of Epidemiological Studies of Prenatal DEHP Exposure and Selected Neurodevelopmental Outcomes ................................................................. 239

2-15. Summary of Epidemiological Studies of Prenatal DEHP Exposure and Reproductive Development in Males ................................................................. 256

2-16. Summary of Epidemiological Studies of DEHP Exposure and Reproductive Development in Females ................................................................. 276

2-17. Selected Epidemiological Studies of DEHP Exposure and Diabetes or Glucose Homeostasis .... 289

2-18. Genotoxicity of DEHP In Vitro .................................................................................. 301

2-19. Genotoxicity of MEHP In Vitro ................................................................................. 304

2-20. Genotoxicity of DEHP In Vivo .................................................................................. 306

2-21. Genotoxicity of MEHP In Vivo .................................................................................. 307
5-16. Creatinine Corrected MECPP Concentrations for the U.S. Population from NHANES 2003–
2014 ................................................................................................................................................. 407
5-17. FDA Estimates of DEHP Exposures Resulting from Medical Treatments......................... 418
6-1. Ongoing Studies on DEHP ........................................................................................................... 427
7-1. Regulations and Guidelines Applicable to DEHP ....................................................................... 429